Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01366573 · ClinicalTrials.gov registry record · Phase 1
GSK1521498 Alcohol Interaction Study
A Phase 1 study of Alcoholism, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT01366573: Completed Phase 1 study of Alcoholism, sponsored by GlaxoSmithKline.
NCT01366573 is a Phase 1 study of Alcoholism that has completed, run by GlaxoSmithKline. The registered enrollment target is 1 participants, below the 375-participant average among 65 other Alcoholism trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01366573, a Phase 1 study of Alcoholism, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of the study is to assess the safety and tolerability of GSK1521498 in combination with alcohol and to determine the amount of GSK1521498 and alcohol in your blood after you have been given these together. The study will also determine whether GSK1521498 will have an effect on alcohol liking and consumption.
Primary Outcome
AUC and Cmax of GSK1521498 and alcohol
Conditions Studied
Interventions
- OTHER Placebo
- DRUG GSK1521498
Study Locations (1)
Texas
- GSK Investigational Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-05-13 |
| Est. Completion | 2011-09-16 |
| Phase | Phase 1 |
What the finished NCT01366573 record still lists
NCT01366573 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 375-participant average among 65 other Alcoholism trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01366573 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01366573 about?
NCT01366573 is a clinical study titled "GSK1521498 Alcohol Interaction Study". The aim of the study is to assess the safety and tolerability of GSK1521498 in combination with alcohol and to determine the amount of GSK1521498 and alcohol in your blood after you have been given these together. The study will also determine whether GSK1521498 will have an effect on alcohol liking...
What is the current status of trial NCT01366573?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2011-05-13. Estimated completion is 2011-09-16.
What conditions does trial NCT01366573 study?
This clinical trial studies the following conditions: Alcoholism.
What interventions are being tested in trial NCT01366573?
The interventions under investigation include: Placebo (OTHER), GSK1521498 (DRUG).
Who is sponsoring clinical trial NCT01366573?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01366573 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01366573's enrollment target sits among peer trials
1 66th of 65 the lowest of 65 other Alcoholism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcoholism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
N-acetylcysteine in Alcohol Dependence
COMPLETED · Phase 1
-
Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence
COMPLETED · Phase 1
-
A Novel Compound for Alcoholism Treatment
COMPLETED · Phase 1
-
Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home
COMPLETED · Phase 1
-
Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment
COMPLETED · Phase 1
-
Matching Genotypes and Serotonergic Medications for Alcoholism
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI